Previous research has implicated vascular endothelial growth factor (VEGF) in the
pathogenesis of diabetic retinopathy (DR). Although many studies reviewed the use of anti …

The association of retinal hypoxia with retinal neovascularization has been recognized for
decades, causing Michaelson to postulate in 1948 that a factor secreted by hypoxic retina …

Neovascularization is a common pathological process in various retinal vascular disorders
including diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinal …

The aim of this review is to summarize the latest developments in the treatment of diabetic
retinopathy (DR) with anti‐vascular endothelial growth factor (VEGF) drugs. We reviewed …

The glycosylphosphatidylinositol-anchored transmembrane glycoprotein CD160 (cluster of
differentiation 160) is a member of the immunoglobulin superfamily. Four isoforms, which …

Purpose To quantify the preoperative neovascular change pattern on the fibrovascular
membrane (FVM) within 7 days after intravitreal injection of conbercept (IVC) using optical …

Purpose To determine the timing of neovascular regression after intravitreous injection of
bevacizumab (Avastin®) 1.25 mg given as initial therapy for eyes with high-risk proliferative …

Purpose Anti-vascular endothelial growth factor (VEGF) agents have recently been used
intravitreally during the perioperative period for proliferative diabetic retinopathy (PDR) …

Background To investigate the role of CYR61 as a retinal angiogenic factor in proliferative
diabetic retinopathy (PDR). Methods Effects of CYR61 on RF/6A cell proliferation, migration …

Objetivo: evaluar el efecto de la fotocoagulación panretinal e inyección intravítrea de
bevacizumab sobre las áreas de neovascularización en pacientes con retinopatía diabética …